Company intelligence / Profile preview

Prolium Bioscience

Ownership: Private
Development stage: Other

Overview

Prolium Bioscience is a US-based biotech founded and funded by RTW Investments. Its lead asset, ICP-B02 (CM355), a CD20×CD3 bispecific antibody, is in Phase 1/2 trials in China for relapsed/refractory non-Hodgkin lymphoma, showing promising early activity. Prolium has in-licensed global rights for non-oncology indications and ex-Asia oncology indications for ICP-B02 from KeyMed Biosciences and InnoCare Pharma, with plans for dose-expansion and combination studies.

Therapeutic areas: OncologyOther
Modalities: Bispecific monoclonal antibody
Industry: Biotech

Partnerships

KeyMed BiosciencesInnoCare PharmaRTW Investments

Beyond the preview

Go deeper on Prolium Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prolium Bioscience.